H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Oncorus (ONCR - Research Report) today and set a price target of $7.00...
0001671818false00016718182022-08-042022-08-04 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549 ...
Additional clinical data from ONCR-177 surface lesion monotherapy and combination expansion cohorts expected in...
us68236r1032_070822.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the...
false000167181800016718182022-06-222022-06-22 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549 ...
-Former CEO of Dicerna brings deep expertise in RNA research, drug development, business development and...
CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies...
FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...
CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies...
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549...
0001671818false00016718182022-05-102022-05-10 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549 ...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.